Angiogenesis and antiangiogenic therapy in endometriosis

Becker CM, Christian M Becker, D'Amato RJ, Robert J D'Amato, Robert J. D’Amato
Microvascular research · 2007 · vol. 74(2-3) , pp. 121–130 · doi:10.1016/j.mvr.2007.04.008 · PMID:17574280 · W2023282968
review OA: closed CC0 ⤵ 88 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper reviews the role of angiogenesis and antiangiogenic therapies in the context of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis, the presence of endometrium-like tissue outside of the uterine cavity, is a common disease among women of reproductive age. Typical symptoms include abdominal pain and painful menstruation. In addition, endometriosis is associated with reduced fertility. Current treatment modalities, the surgical removal of endometriotic lesions and the hormonal suppression of estrogen are associated with significant morbidity, side-effects and recurrence rates. Despite uncertainties about the pathophysiology of the disease it has recently become apparent that angiogenesis plays a pivotal role in endometriosis. This review focuses on a multitude of factors involved in the angiogenic phenotype of endometriosis demonstrating that many biological systems such as the immune system and steroid hormones are closely connected to angiogenic pathways in this disease. In addition, experimental and clinical data are discussed that concentrate on the inhibition of angiogenesis as a novel therapeutic approach for endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiogenesis Inhibitors Cytokines Endometriosis Hormones Neovascularization, Pathologic Vascular Endothelial Growth Factor A Angiogenesis Inhibitors Animals Cytokines Endometriosis Endometriosis Endometriosis Endometriosis Female Hormones Humans Neovascularization, Pathologic Neovascularization, Pathologic Vascular Endothelial Growth Factor A

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-29T06:27:48.050232+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:14:54.534439+00:00
License: CC0 · commercial use OK